⭐️🚨Just published 👉🏼Pleased to share our standout new review 👉🏼published in @TheLancet @eClinicalMed 👉🏼led by 3 amazing rising stars ⭐️ @JiaJennyLiu @niamhjcoleman @JulianaRBeal 👉🏼“Tumour‑agnostic immunotherapy: aligning biological rationale, biomarker precision, and real‑world implementation.” 👉🏼 Tumour‑agnostic immunotherapy has reshaped precision oncology by showing that, in selected settings, treatment benefit can be driven by a shared biological state rather than anatomical origin. The clearest example: MSI‑H/dMMR cancers, where durable responses span diverse malignancies. ⭐️Such a delight to work with & mentor this dream team 👉🏼their clarity, rigor, and vision shine through every section 🎯🔥 @OncoAlert @oncodaily @OncBrothers thelancet.com/journals/eclin…

🚨Another big win for #precisionmedicine 🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma. ⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- the then CMO of @Relay_Tx “Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram 👉🏼Link to FDA approval fda.gov/drugs/resources-info… 👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdisco…